Stay updated on Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page
- Check5 days agoChange DetectedA Publications section has been added, including the Phase 3 SKYSCRAPER-06 article citation (JAMA Oncol. 2026) with DOI and author list, plus a note that publications are auto-filled from PubMed.SummaryDifference0.1%

- Check12 days agoChange DetectedThe page’s footer/site release revision was updated from **v3.5.0** to **v3.5.3**.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedSite version updated from v3.4.3 to v3.5.0. The study information remains unchanged.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

- Check85 days agoChange DetectedMinor revision note updated from v3.4.1 to v3.4.2; no user-facing content or functionality appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check92 days agoChange DetectedAdded Sarah Cannon Research Institute / Tennessee Oncology in Nashville, TN as a recruitment site; total study locations updated from 127 to 128.SummaryDifference0.2%

Stay in the know with updates to Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.